ALPK1 agonists ignite innate immunity in anticancer therapy
Trends in Cancer · 2026-03 · 12 (3) · 209-211
DOI: 10.1016/j.trecan.2026.01.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Cancer, 2026-03. Verfasst von Shreya Mahajan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology and Infectious Diseases, The John Curtin School of Medical Research, The Australian National University, Canberra, Australian …. Hauptthemen laut MEDLINE: Immunity, Innate, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Australian National University, CSL Limited.
Abstract (Originalsprache)
A recent study published in Nature by Tian et al. identifies UDSP-Hep as a synthetic agonist of the innate immune receptor Alpha-protein kinase 1 (ALPK1) that induces enhanced antitumor activity compared with the canonical ALPK1 agonist ADP-Hep and Toll-like receptor or stimulator of interferon genes agonists. UDSP-Hep drives the tumor microenvironment toward a proinflammatory, antitumor state.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Immunology and Infectious Diseases, The John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia.
- Division of Immunology and Infectious Diseases, The John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia. Electronic address: siming.man@anu.edu.a…
Förderung
- National Health and Medical Research Council
- Australian National University
- CSL Limited
Zitieren
APA
Mahajan, S., Bazley, H., & Man, S. M. (2026). ALPK1 agonists ignite innate immunity in anticancer therapy. Trends in Cancer, 12(3), 209-211. https://doi.org/10.1016/j.trecan.2026.01.013
Vancouver
Mahajan S, Bazley H, Man SM. ALPK1 agonists ignite innate immunity in anticancer therapy. Trends in Cancer. 2026;12(3):209-211. doi:10.1016/j.trecan.2026.01.013
BibTeX
@article{Mahajan2026,
author = {Mahajan, Shreya and Bazley, Harrison and Man, Si Ming},
title = {ALPK1 agonists ignite innate immunity in anticancer therapy},
journal = {Trends in Cancer},
year = {2026},
volume = {12},
number = {3},
pages = {209--211},
doi = {10.1016/j.trecan.2026.01.013}
}
EUVIMED